Methylprednisolone · oral tablet
Steroid
Approved uses
Severe ocular allergic and inflammatory disease, including herpes zoster ophthalmicus, anterior segment inflammation, diffuse posterior uveitis and choroiditis, sympathetic ophthalmia and optic neuritis
Initial dosage 4 mg to 48 mg per day depending on the specific disease entity, reduced in small decrements to the lowest effective maintenance dosage; after long-term therapy, withdraw gradually rather than abruptly
The label's ocular list is specific: this is one of the few systemic steroids with named ophthalmic indications
Contraindications
- Systemic fungal infections
- Known hypersensitivity to components
2 mg bottles of 100, 4 mg bottles of 100 and 21-tablet DOSEPAK, 8 mg bottles of 25, 16 mg bottles of 50, 32 mg bottles of 25
MEDROL Tablets contain methylprednisolone, which is a glucocorticoid. Synthetic glucocorticoids are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects, and they modify the body's immune responses to diverse stimuli. High levels of cortisol stabilize lysosomal membranes, decrease capillary permeability (probably as a secondary effect of reduced release of proteolytic enzymes), decrease migration of white blood cells into the inflamed area, and suppress the immune system.
Warnings & Precautions
- Unusual stress: In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.
- Immunosuppression and increased risk of infection: Corticosteroids suppress the immune system and increase the risk of infection with any pathogen. They can reduce resistance to new infections, exacerbate existing infections, increase the risk of disseminated infections or of reactivation or exacerbation of latent infections, and mask some signs of infection. Infections can be severe and at times fatal, and their rate rises with dosage. Monitor for infection; consider withdrawal or dosage reduction as needed.
- Tuberculosis: If MEDROL is used in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur. Closely monitor such patients for reactivation. During prolonged MEDROL therapy, these patients should receive chemoprophylaxis.
- Varicella zoster and measles viral infections: Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, so particular care should be taken to avoid exposure. After exposure to varicella, prophylaxis with varicella zoster immune globulin may be indicated, and antiviral treatment may be considered if varicella develops. After exposure to measles, prophylaxis with immunoglobulin may be indicated.
- Hepatitis B virus reactivation: Reactivation can occur in hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, and infrequently in patients who appear to have resolved hepatitis B infection. Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment. For patients with evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B.
- Fungal infections: Corticosteroids may exacerbate systemic fungal infections, so avoid MEDROL in the presence of such infections unless it is needed to control drug reactions. For patients on chronic MEDROL therapy who develop systemic fungal infections, MEDROL withdrawal or dosage reduction is recommended.
- Amebiasis: Corticosteroids may activate latent amebiasis. Rule out latent or active amebiasis before initiating MEDROL in patients who have spent time in the tropics or patients with unexplained diarrhea.
- Strongyloides hyperinfection: Use with great care in patients with known or suspected Strongyloides (threadworm) infestation. Corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.
- Cerebral malaria: Avoid corticosteroids, including MEDROL, in patients with cerebral malaria.
- Ophthalmic effects: Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses. Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.
- Kaposi's sarcoma: Kaposi's sarcoma has been reported in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement.
- Hypertension, volume overload, and hypokalemia: Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.
- Vaccination: Live or live, attenuated vaccines are contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be given, but the response may be diminished.
- Drug-induced secondary adrenocortical insufficiency: It may be minimized by gradual reduction of dosage and may persist for months after discontinuation, so hormone therapy should be reinstituted in any situation of stress during that period. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be given concurrently.
- Complications of treatment: Complications depend on the size of the dose and the duration of treatment, so a risk/benefit decision must be made in each case as to dose, duration, and daily or intermittent therapy. Use the lowest possible dose, and make any dosage reduction gradual.
- Enhanced effect: There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis.
- Psychic derangements: Psychic derangements may appear, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Existing emotional instability or psychotic tendencies may be aggravated.
- Scleroderma renal crisis: Caution is required in patients with systemic sclerosis because an increased incidence of scleroderma renal crisis has been observed with corticosteroids, including methylprednisolone.
- General precautions: Steroids should be used with caution in nonspecific ulcerative colitis if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis.
- Tumor lysis syndrome: TLS has been reported in patients with malignancies, including hematological malignancies and solid tumors, following systemic corticosteroids alone or with other chemotherapeutic agents. Monitor patients at high risk of TLS closely and take appropriate precautions.
Common Side Effects
Reactions include sodium retention, congestive heart failure in susceptible patients, hypertension, fluid retention, potassium loss and hypokalemic alkalosis; muscle weakness, steroid myopathy, osteoporosis, tendon rupture, vertebral compression fractures and aseptic necrosis of femoral and humeral heads; peptic ulcer with possible perforation and hemorrhage, pancreatitis and ulcerative esophagitis; impaired wound healing and thin fragile skin; increased intracranial pressure with papilledema usually after treatment, convulsions, vertigo and headache; Cushingoid state, suppression of growth in children, secondary adrenocortical and pituitary unresponsiveness, menstrual irregularities and manifestations of latent diabetes mellitus; posterior subcapsular cataracts, increased intraocular pressure, glaucoma and exophthalmos; and allergic, anaphylactic or hypersensitivity reactions.
Pregnancy: Adequate human reproduction studies have not been done with corticosteroids, so the possible benefits of the drug must be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.
Lactation: Since adequate human reproduction studies have not been done with corticosteroids, use in nursing mothers requires that the possible benefits of the drug be weighed against the potential hazards.
Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed. Suppression of growth in children is a listed adverse reaction.